AstraZeneca (AZN)
(Delayed Data from NSDQ)
$81.81 USD
+0.61 (0.75%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $81.20 -0.61 (-0.75%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$81.81 USD
+0.61 (0.75%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $81.20 -0.61 (-0.75%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
by Kinjel Shah
AstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase cost reduction program.
Why Astrazeneca (AZN) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
by Zacks Equity Research
AstraZeneca (AZN) targets $80 billion in total revenues by 2030. It expects to launch 20 new medicines.
AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
by Zacks Equity Research
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
by Zacks Equity Research
Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Ironwood (IRWD) incurs loss in the first quarter of 2024. Revenues decline year over year and miss estimates. The company lowers revenue guidance for 2024. Stock falls.
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Ionis (IONS) posts mixed first-quarter 2024 results. The company continues to focus on pipeline development.
Why Astrazeneca (AZN) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
The Zacks Analyst Blog Highlights AstraZeneca, Qualcomm, FedEx, American International and Baker Hughes
by Zacks Equity Research
AstraZeneca, Qualcomm, FedEx, American International and Baker Hughes are included in this Analyst Blog.
Top Analyst Reports for AstraZeneca, QUALCOMM & FedEx
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), QUALCOMM Incorporated (QCOM) and FedEx Corporation (FDX).
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
by Zacks Equity Research
Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
by Kinjel Shah
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs.
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
by Zacks Equity Research
Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024. Stock rises in pre-market.
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
by Zacks Equity Research
Sanofi (SNY) posts first-quarter 2024 results and maintains the earnings growth guidance for the year.
Q1 GDP Increased Lower Than Expectations
by Zacks Equity Research
Q1 GDP Increased Lower Than Expectations
Is "Bad News" Still "Good News" for the Market?
by Mark Vickery
If we're looking for the Fed to lower interest rates, don't we need softer economic data like what we saw today?
Astrazeneca (AZN) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Astrazeneca (AZN) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.
Insights Into Astrazeneca (AZN) Q1: Wall Street Projections for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Astrazeneca (AZN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Astrazeneca (AZN) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.